

Launching a new medicine – Training workshop Thursday 26th October 2023

10.00 - 10.15 Welcome and plan for the day

Renata Scalco – Global Development Leader, Roche

10.15 - 10.45 What critical attributes make a drug a drug

Lutz Mueller – Toxicology Project Leader, Roche

10.45 - 11.15 Regulatory perspective of drug development

Lesley Narburgh – Global Franchise Regulatory Head, Rare diseases and Neurodegeneration, Roche

11.15 - 11.45 Breakout tutorial session (attributes of a drug)

Lutz Mueller and Lesley Narburgh, Roche

11.45 - 12.00 Break

12.00 - 12.30 Review and decision – When is it safe to go into humans?

David Jones – Consultant Pharmaco-Toxicologist

12.30 - 13.00 Clinical pharmacology evidence building

Helen Tomkinson – Managing Director, Limina Clinical Pharmacology

13.00 - 13.45 Lunch

13.45 - 14.15 Breakout tutorial session (Clinical PK)

Helen Tomkinson – Managing Director, Limina Clinical Pharmacology

14.15 - 14.45 Indication selection – proactive and reactive risks

Aaron Deveney – Vice President Clinical Development, Weatherden

14.45 - 15.15 Breakout tutorial session (indication selection problem)

Aaron Deveney – Vice President Clinical Development, Weatherden

15.15 - 15.25 Break

15.25 - 15.55 The clinical regulatory perspective

Kirsty Wydenbach – Head of Regulatory Strategy, Weatherden

15.55 - 16.25 Breakout tutorial session (regulators discussion - labels)

Kirsty Wydenbach – Head of Regulatory Strategy, Weatherden

16.25 - 16.30 Wrap-up and confirmation of the Learning Outcomes

Renata Scalco - Project lead, Roche